Form 4 for BIVI BIOVIE INC.
Accepted 2023-12-06 00:00:00 ET · period of report 2023-11-09 · accession 0001520138-23-000534 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-06 | 2023-11-09 | BIVI | GORLIN STEVE | Dir | A - Grant | $0.00 | +46.4K | 122.0K | +61% | $0 | |
| 2023-12-06 | 2023-12-01 | BIVI | GORLIN STEVE | Dir | S - Sale | $1.69 | -75.7K | 46.4K | -62% | -$127.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-09 | A | A | 46,358 | $0.00 | 122,038 | D | — | — | (F1) The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on September 22, 2023, subject to board approval, which was obtained on November 9, 2023. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments beginning on February 9, 2024, with the remaining installments vesting on May 9, 2024, August 9, 2024 and the earlier of November 9, 2024 or the date of the issuer's 2024 annual shareholders' meeting. |
| 2 | Common | Common Stock | 2023-12-01 | S | D | 75,680 | $1.69 | 46,358 | D | — | — |